An interventional study of Proactive CPAP Therapy and Conventional APAP Therapy in Obstructive Sleep Apnea, sponsored by NovaResp Technologies Inc. Completed at 1 site in Canada. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by NovaResp Technologies Inc · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 133 studies in Sleep Apnea, Obstructive with a site in Canada — 22 open to participants now, 31 under way, 4 of them phase 3. Sleep Apnea, Obstructive · Canada.
Among the 133 studies in Sleep Apnea, Obstructive with a site in Canada, this one is the 37th largest by enrollment of the 102 interventional ones that give a count, is one of 6 that started in 2024, is one of 70 with no phase, and was the 117th registered.
2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.
Browse Sleep Apnea, Obstructive studies →22 of the 133 studies in Sleep Apnea, Obstructive with a site in Canada are open now. Recruiting first, the newest first:
The Hospital for Sick Children · Sites in Canada
Ages 2–18
Eli Lilly and Company · Sites in Canada, United States, Australia and 8 more countries
Ages 18+
University of British Columbia · Sites in Canada
Ages 19+ · Healthy volunteers
University of Alberta · Sites in Canada
Ages 18+
Lena Xiao · Sites in Canada
Ages 6–18
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
133 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 3 · Phase 3 19 · Phase 4 7
First in 2003; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 96 is above the median of 52 across 1,476 interventional studies indexed under Sleep Apnea, Obstructive.
Median enrollment 60 across the 102 interventional studies, 100 across the 31 observational. Of the 86 that completed or were terminated, 10 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 133 have an industry lead sponsor. The 10 most frequent:
NovaResp Technologies Inc is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
NovaResp Technologies Inc has 3 studies filed under Sleep Apnea, Obstructive — fewer than ten, so there is no comparison to draw.
9 of the studies in Sleep Apnea, Obstructive with a site in Canada that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07225686Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | 2027-08-20 |
| NCT07226765Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy | 2027-08-30 |
| NCT05678088Sunnybrook Health Sciences CentreOropharyngeal Exercises to Treat Obstructive Sleep Apnea | 2026-12 |
| NCT04187612Samuel Lunenfeld Research Institute, Mount Sinai HospitalAssociation of Body Fluid Distribution With Obstructive Sleep Apnea in Pregnant Women With Body Mass Index ≥ 40 kg/m2 | 2026-12 |
| NCT07301567University of British ColumbiaPilot Study of Negative Pressure Neck Therapy (NPNT) | 2026-12 |
Add all 9 to your calendar (.ics) → With an account.
Among the 133 studies in Sleep Apnea, Obstructive with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to compare the adherence to Positive Airway Pressure (PAP) therapy for newly diagnosed Obstructive Sleep Apnea (OSA) patients. The main question(s) it aims to answer are:
This is a double-blind, randomized controlled superiority trial on newly diagnosed patients with obstructive sleep apnea. Each participant will be provided with a APAP device. The devices assigned to the test group will be modified to deliver the proactive therapy using Artificial Intelligence (AI). Devices assigned to the control group will deliver the conventional APAP therapy. A sleep technician will be in regular contact with participants and track the time spent interacting with each participant. At the conclusion of the first 3 months of the trial, participants who are acceptant to therapy will be asked if they would like to continue participating for an additional 9 months. Data will be collected by the PAP device and a series of self-reported questionnaires.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will undergo CPAP enabled with proactive therapy.
Device: Proactive CPAP Therapy
Patients will undergo conventional APAP therapy.
Device: Conventional APAP Therapy
CPAP machine uses Artificial Intelligence to make predictions and preventions of future apneic events to auto-adjust pressure.
CPAP machine relies on the detection of respiratory events to determine how to react and auto-adjust pressure.
Adherence
Calculated as at least 70% compliance (at least 4 hrs), in 30 days
Time frame: 3-12 months
Apnea-Hypopnea Index
Calculated as the mean number of apnea and hypopnea events throughout the night in events/hr.
Time frame: 3-12 months
CPAP Therapy Usage
Calculated as the mean device usage by the patient throughout the night.
Time frame: 3-12 months
Self-assessed sleep outcomes
Patients will be requested to fill out a questionnaire to help evaluate their sleepiness before and after therapy. Scale: Epworth Sleepiness Scale on a 7-point scale, higher values meaning worse outcome.
Time frame: 3-12 months
Self-assessed functional outcomes
Patients will be requested to fill out a questionnaire to help evaluate their functional outcomes of sleep before and after therapy. Scale: Functional Outcomes of Sleep Questionnaire on a 7-point scale, higher values meaning better outcomes.
Time frame: 3-12 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2024 to primary completion in Apr 2026, 21 months.
Of 118 industry-sponsored interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 21. This study's 21 months is above that.
Counting every sponsor, half of 629 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Jun 2025 → Apr 2026 and completion Jun 2025 → Apr 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
NovaResp Technologies Inc